Lab chemist interview questions and answers – HPLC chromatogram and OOS question card

Lab Chemist Interview Questions and Answers: 50 QC Questions (60 characters)

Interview prep · Pharma QC

Lab chemist interview questions and answers in pharmaceutical QC test five areas: GMP and data integrity (ALCOA+), analytical instruments (HPLC, GC, UV-Vis, FTIR, Karl Fischer, dissolution), method validation under ICH Q2(R2), how you handle OOS results and deviations, and stability testing. The 50 questions below come up repeatedly in QC chemist interviews at formulation plants, and the answers are written to the standards in force in November 2026.

Standards interviewers now expect you to quote

Many question banks still cite superseded versions. If you are asked about guidelines, use these:

  • Method validation: ICH Q2(R2), adopted at Step 4 on 1 November 2023, with its companion ICH Q14 on analytical procedure development. Quote these, not Q2(R1).[1][2]
  • Quality risk management: ICH Q9(R1), Step 4 on 18 January 2023.[3]
  • Elemental impurities: ICH Q3D(R2).[4]
  • Indian Pharmacopoeia: IP 2026, the 10th edition, released by the Indian Pharmacopoeia Commission in January 2026 with 121 new monographs (3,340 in total).[5]
  • Stability: ICH Q1A(R2) still applies. A consolidated ICH Q1 revision was scheduled for Step 4 adoption in November 2026, so check the ICH website before your interview.[6][7]

50 lab chemist interview questions and answers

Tap a question to see the answer. Use Save as PDF to keep a copy for revision.

References

  1. International Council for Harmonisation. ICH Q2(R2) Validation of Analytical Procedures. Step 4 version, 1 November 2023. Amsterdam: European Medicines Agency; 2023. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q2r2-guideline-validation-analytical-procedures-step-5-revision-1_en.pdf. Accessed November 2026.
  2. International Council for Harmonisation. ICH Q14 Analytical Procedure Development. Step 4 version, 1 November 2023. Amsterdam: European Medicines Agency; 2023. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q14-guideline-analytical-procedure-development-step-5-revision-1_en.pdf. Accessed November 2026.
  3. International Council for Harmonisation. ICH Q9(R1) Quality Risk Management. Step 4 version, 18 January 2023. Brussels: European Commission; 2023. Available from: https://health.ec.europa.eu/system/files/2023-10/mp_ich_q9guideline-ra_en.pdf. Accessed November 2026.
  4. European Medicines Agency. ICH Q3D Elemental impurities — Step 5, Revision 2 (legal effective date 24 September 2022). Amsterdam: EMA; 2022. Available from: https://www.ema.europa.eu/en/ich-q3d-elemental-impurities. Accessed November 2026.
  5. Indian Pharmacopoeia Commission. Union Health Minister releases 10th Edition of Indian Pharmacopoeia — IP 2026. Ghaziabad: IPC; 2026. Available from: https://www.ipc.gov.in/news-highlights/1421-union-health-minister-shri-j-p-nadda-releases-10th-edition-of-indian-pharmacopoeia-ip-2026.html. Accessed November 2026.
  6. International Council for Harmonisation. ICH Q1A(R2) Stability Testing of New Drug Substances and Products. Step 4 version, 6 February 2003. Geneva: ICH; 2003. Available from: https://database.ich.org/sites/default/files/Q1A(R2)%20Guideline.pdf. Accessed November 2026.
  7. International Council for Harmonisation. ICH Q1 Expert Working Group Work Plan (Q1/Q5C revision of the stability guideline series). Geneva: ICH; 2026. Available from: https://database.ich.org/sites/default/files/ICH52_Q1_EWG_WorkPlan_2026_0318.pdf. Accessed November 2026.
  8. World Health Organization. Annex 4: WHO Guideline on data integrity. WHO Technical Report Series No. 1033. Geneva: WHO; 2021. Available from: https://www.who.int/publications/m/item/annex-4-trs-1033. Accessed November 2026.
  9. US Food and Drug Administration. Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production — Guidance for Industry, Level 2 revision. Silver Spring (MD): FDA; May 2022. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigating-out-specification-test-results-pharmaceutical-production. Accessed November 2026.
  10. World Health Organization. Annex 10: Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. WHO Technical Report Series No. 1010. Geneva: WHO; 2018. Available from: https://extranet.who.int/prequal/sites/default/files/document_files/TRS1010_Annex10.pdf. Accessed November 2026.
  11. United States Pharmacopeia. General Chapter <1058> Analytical Instrument Qualification (version official 1 August 2017). Rockville (MD): USP; 2017. Available from: https://doi.usp.org/USPNF/USPNF_M1124_10101_01.html. Accessed November 2026.

Educational content for interview preparation, not legal or regulatory advice. Pharmacopoeial texts, ICH guidelines and Indian statutory instruments are revised frequently; confirm the current version with the issuing body before relying on a limit or date.

Darshan Singh
Darshan Singh

Author is a pharmaceutical quality and regulatory professional with more than 23 years in drug manufacturing. He holds an M.Sc. in Organic Chemistry and a Diploma in Pharmacy. He has served as Quality Control Head, Quality Assurance Head and Plant Head, overseeing all manufacturing operations. He is co-founder and regulatory consultant at Laafon Galaxy Pharmaceuticals. He writes on SOPs, manufacturing processes, Schedule M compliance and drug pharmacology, and checks each claim against pharmacopoeial and regulatory sources.

Articles: 242